EGFR and non-small cell lung carcinoma: In the attempt to find predictive biomarkers for EGFR-mutated NSCLC patients, our group highlighted that mutations in TP53 are able to influence responsiveness to first-line first- and second-generation TKIs in a case series of 136 EGFR-mutated NSCLC patients.